RNA Formulation Videos
-
What Does 2025 (And Beyond) Hold For The RNA-LNP Space?
12/4/2024
Three LNP experts share their thoughts on the incremental advancements they’d like to see the RNA-LNP space make in the next few years.
-
Simplify CAR-T Cell Manufacturing With LNP-Mediated Delivery
6/3/2025
Streamline CAR-T cell manufacturing with lipid nanoparticles delivering base editors to create fratricide-resistant, CD45-edited CAR45 T cells, which enables scalable, precise, and potent therapies for blood cancers.
-
Flexible Liquid Nanoparticle (LNP) Systems
12/6/2024
From research and clinical studies to full-scale production, revolutionize your lipid nanoparticle (LNP) production with flexible and scalable solutions.
-
Q&A On LNP Cell-Specific Delivery
11/28/2022
In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery for Strand Therapeutics, outline several examples of foundational research that could provide insights into how we attain more specific cellular uptake of LNPs.
-
How To Bring Your LNP Formulation To Clinical/Commercial Manufacturing
5/23/2024
Gain valuable insights into key considerations when selecting lipid excipients for LNP formulations and the process development steps necessary to advance them to GMP manufacturing and clinical trials.
-
RNA Vaccine Development To Phase I
4/14/2022
Dr. John Lewis, Founder and CEO, Entos Pharmaceuticals, presents RNA Vaccine Development to Phase I.
-
In What Ways Are We Underestimating LNP Complexity Today?
12/4/2024
As the RNA-LNP space continues to diversify beyond linear mRNA and infectious disease vaccines, Kate Zhang of Hopewell Therapeutics, Sumit Luthra of Sanofi, and Ben Muir of BioNTech each address several misconceptions about LNP composition today and how the rise of novel RNA modalities, more advanced mechanisms of action, and novel lipids are challenging our understanding of/work with LNPs today.
-
An Early Formulation Screening Service
5/23/2024
Gain insights into overcoming the challenges in lipid nanoparticle (LNP) formulation, explore critical aspects of the process and analytical development of LNPs, and much more.
-
Q&A On Formulation & Stability Of LNPs
11/28/2022
Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, address audience questions around the importance of drug substance and drug product stability in efficient delivery in this segment of the Bioprocess Online Live! event LNPs & Beyond: Opportunities in RNA Delivery.
-
Insights And Strategies For GMP Manufacturing Of RNA-Lipid Nanoparticles
4/25/2024
The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?